Navigation Links
Mothers and Youth Sports Nationwide Push for FabricAide in Response to MRSA Threat
Date:1/16/2008

s sometimes do have to share uniforms or towels."

"MRSA has become an epidemic of sorts and is emerging as one of the main causes of critical illness in children including young athletes," said Dr. Thomas Shaney, C.S. Mott Children's Hospital.

Groups across the country have adopted FabricAide and are recommending it to their constituents. Moms Team, a prominent national organization of mothers who promote safety in youth sports, feature FabricAide prominently on their website http://www.momsteam.com. The North American Booster Club Association also recommends that its members raise money through the CSG/SportsCoatings FabricAide fundraising program. To find out how more about FabricAide please call 1.3888.510.2847 or visit http://www.csgsportscoatings.com.


'/>"/>
SOURCE CSG/SportsCoatings
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. FDA Warns of Codeine Risk for Some Nursing Mothers
2. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
3. Hip size of mothers linked to breast cancer in daughters
4. Overweight mothers run greater risk of having hyperactive children
5. HIV drug resistance risk in mothers reduced by combination of common drugs
6. Smoking and depression often co-occur in new mothers
7. Mothers stress may increase childrens asthma
8. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
9. Study documents rapid increase in youth bipolar disorder diagnoses
10. Rates of bipolar diagnosis in youth rapidly climbing, treatment patterns similar to adults
11. Youth Drug Use at a Five Year Low, New Survey Shows
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:REES Announces New Baltimore Office 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Buffalo Personal Injury Lawyers Cellino & Barnes Donate $1M to UB School of Law, Appear on Cover of School's Philanthropy Magazine 2
Other Medicine News:Health News:Texas Cancer Organizations Urge State Legislature to Fully Fund the Cancer Prevention and Research Institute of Texas 2Health News:Gen-Probe Reports Financial Results for First Quarter 2009 2Health News:Gen-Probe Reports Financial Results for First Quarter 2009 3Health News:Gen-Probe Reports Financial Results for First Quarter 2009 4Health News:Gen-Probe Reports Financial Results for First Quarter 2009 5Health News:Gen-Probe Reports Financial Results for First Quarter 2009 6Health News:Gen-Probe Reports Financial Results for First Quarter 2009 7Health News:Gen-Probe Reports Financial Results for First Quarter 2009 8Health News:Gen-Probe Reports Financial Results for First Quarter 2009 9Health News:Gen-Probe Reports Financial Results for First Quarter 2009 10Health News:Gen-Probe Reports Financial Results for First Quarter 2009 11Health News:Gen-Probe Reports Financial Results for First Quarter 2009 12Health News:Gen-Probe Reports Financial Results for First Quarter 2009 13Health News:Gen-Probe Reports Financial Results for First Quarter 2009 14Health News:Gen-Probe Reports Financial Results for First Quarter 2009 15Health News:Gen-Probe Reports Financial Results for First Quarter 2009 16Health News:Gen-Probe Reports Financial Results for First Quarter 2009 17Health News:Gen-Probe Reports Financial Results for First Quarter 2009 18Health News:Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic 2Health News:Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic 3Health News:Chlamydia may play role in a type of arthritis 2
Other Medicine Technology:Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5